Epitomie CEO Aims for Direct-to-Consumer Sales in US Weight-Loss Market
Epitomie Medical's stock experienced a dramatic surge of over 70% in a single day, following a prior 15% increase, despite no specific company announcements. This rally has brought the company's market value to approximately 120 million shekels (around $32 million USD).
Dr. Dolev Refaeli, who recently took over as CEO, believes the company's past failures were not due to its weight-loss capsule product but rather its distribution strategy. He stated, "The problem was the channel, not the product." Refaeli, with extensive experience in building and marketing medical products directly to consumers in the US, plans to shift Epitomie's focus from relying on distributors to a direct-to-consumer (DTC) model in the American market.
Refaeli aims to leverage the existing market education driven by GLP-1 drugs, which have significantly increased consumer awareness and willingness to seek medical solutions for obesity. He sees an opportunity in patients who discontinue GLP-1 treatments due to side effects or cost, or those seeking maintenance after weight loss. Epitomie's product, an FDA-approved medical device that creates a feeling of fullness without systemic absorption, is positioned as a safer alternative with fewer side effects.
The company faces challenges, including the need for significant capital to fund its DTC strategy and competition from established pharmaceutical companies. Refaeli acknowledges the need for further funding, stating, "A company at our stage, entering the American market, requires capital." He also noted that while the stock has surged, the company's actual revenue generation from its FDA-approved product has been limited, and the focus must now be on proving its commercial viability.
Epitomie's strategy involves building a direct commercial operation in the US, focusing on telemedicine partnerships and direct marketing. Refaeli brings a team with proven experience in DTC medical product launches, aiming to replicate past successes where similar strategies led to substantial sales growth. The company's manufacturing capacity in Israel is also being scaled to support anticipated demand.
